Last reviewed · How we verify

NCT04360616

The Diagnosis and Prognosis of Nonpalpable Breast Cancer Detected by the US vs Mammography: a Clinical Noninferiority Trial.

Status unknown Last updated 25 January 2022
What this trial tests

trial testing imaging in Breast Cancer in 1,277 participants. Status unknown.

Timeline
1 April 2020
Primary endpoint
31 March 2023
31 March 2023

Quick facts

Lead sponsorThe First Affiliated Hospital of the Fourth Military Medical University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,277
Start date1 April 2020
Primary completion31 March 2023
Estimated completion31 March 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The First Affiliated Hospital of the Fourth Military Medical University

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate and compare the sensitivity, specificity, AUC, pathology results of core needle biopsy and surgical pathology results coincidence rate, tumor staging, and DFS (disease-free survival) of US-detected nonpalpable breast cancer vs mammography-detected nonpalpable breast cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of imaging

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other The First Affiliated Hospital of the Fourth Military Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04360616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing